Part
01
of one
Part
01
Who are the top 10 small to mid-sized pharma companies in Argentina, who have good growth prospects, a proven business model, and could benefit from investment to help expand?
Hello! Thanks for asking to provide you with a list of the top 10 small to mid-sized pharma companies in Argentina, who have good growth prospects, a proven business model, and could benefit from investment to help expand. The sources I found most helpful in answering your question are Pharma Boardroom and Pharm Exec Country Report. In short, the 7 companies with verifiable information that fit your parameters are Gador, Elea, Casasco, Baliarda, Investi, Bernabo, and Savant. I have provided details on them below. Please read on for research details.
BACKGROUND
To start, I defined small and midsize businesses according to Gartner, where the definition is based on both revenue and number of employees. In my research I was unable to find 10 companies that fully fit the parameters you set for this search, however, I found 7 companies with verifiable information.
I looked to pharma industry reports to get an idea of the state of the market. I pulled the companies from the pharmaexec (PE) Argentina report. I did this by using their Figure 2 list of top 20 companies, then weeded out those that did not fit this request's qualifications (they were either too big, had revenues that were too high, or were multinational and not based in Argentina). I provided investment information where available (such as from Bloomberg), but this is not extensive due to the dearth of information.
For this research, I worked under the assumption that your guidelines would qualify a company for whatever your investment needs are. I used LinkedIn as my primary resource for a company’s number of employees, and a combination of Owler, Data Fox, Hoover’s, and Manta for revenues. Not all of the revenues were publicly available. When they were unavailable, I referred to the sales in USD from PE’s Figure 2. The information presented in the figure is based on October 2013 through October 2014 findings, which are the most recent free-access or published reports. Due to the limited information and lack of updated information, I was unable to provide updated growth prospects for each company. Instead, I used the market share from 2013-2014 for the basis of stability.
Gador ranks 3rd in pharmaexec (PE) with 4.39% of the market share. According to their LinkedIn page, they have 501-1000 employees. Their high market share (the highest market share belonged to the foreign company Roemmers, at 9.08%) shows growth prospects. Gador's revenue is $258.202 million, according to Hoovers. 1.5 million patients use Gador's products monthly.
Elea is Gador's closest competitor, ranking 4th in the pharmaexec (PE). According to their LinkedIn page, they employ 501-1,000 people. The PE Figure notes that their sales were $260 million. Francisco Cervo, the General Manager of Elea Argentina, says that Elea would like to move in with new projects, which I thought would be of special interest to you based on your investment-based request. Until 1973 when this company changed its name, it was previously known as Argentine Endocrine Laboratory Ltd. The company was founded in Buenos Aires, Argentina in 1939.
Laboratorios Casasco ranks 9th in PE's figure with 4.11% of the market. The company has sales of $250 million, with a staff base of 501-1000 employees.
Baliarda's website is entirely in Spanish, a colleague who speaks Spanish helped with this research, translating and paraphrasing Baliarda are values that's listed on their company page to make it easier. The company focuses on high-quality, efficient, and reasonably priced pharmaceuticals. They also employ over 700 people, have 10 laboratories, and is listed as one of the top 10 pharmaceutical companies in the country. Baliarda's revenue was not publicly available but their 2013-2014 sales were $214 million, and they held a market share of 3.51%.
Investi's primary lines of focus are primary lines focus on respiratory, contraceptive, psychiatric, dermatologic, and metabolic medication. Investi Farma does not have its own LinkedIn page.
Bernabo's staff size is estimated to be 501-1000 employees, according to the company's LinkedIn page. They were ranked 14th on PE's figure, with a market share of 2.2%. As of present, Laboratorios Bernabo has produces 93 pharmaceutical products in as much as 163 presentations, covering both medicine and odontology therapeutical lines.
Savant wasn't ranked on PE's figures. The company says that they have 201-500 employees. Savant, on their website, alluded to their revenue (although not publicly available) mentioning that it multiplied dramatically in from 2005 through 2012, by as much as 1,200%; in the same period they grew their client base by 1000%, equipment effectiveness grew 100%, they achieved a revenue per employee of 350% and hit employee satisfaction of 80%. The company's CEO is 41 years old Mr. Hernán Giovanini; the company has plans to expand into Brazil and Chile.
CONCLUSION
In summary, the 7 companies with verifiable information that fit parameters are Gador, Elea, Casasco, Baliarda, Investi, Bernabo, and Savant. I have provided details on them above.
Thanks for using Wonder! Please let us know if you need more help with your research.